Fliser D, Lorenzo MM, Houghton K, Ainsworth C, Blogg M, Gonzalez de Antona Sanchez E, Portles J. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-29. doi: 10.2147/IJNRD.S401598
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol. 2010 Jun;15(2):151-7.
Dubrey SW, Gnanasakthy A, Stein WK, Song JG, Hardman T, Hynd J, Noble MI. Enoximone in chronic stable angina: a double-blind placebo-controlled cross-over trial. J Cardiovasc Pharmacol. 1994 Apr;23(4):532-8.